---
title: "Summit Therapeutics Inc. (SMMT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SMMT.US.md"
symbol: "SMMT.US"
name: "Summit Therapeutics Inc."
industry: "Biotechnology"
datetime: "2026-05-20T14:34:18.741Z"
locales:
  - [en](https://longbridge.com/en/quote/SMMT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SMMT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SMMT.US.md)
---

# Summit Therapeutics Inc. (SMMT.US)

## Company Overview

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.smmttx.com](https://www.smmttx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.20 | 457 | - | - | - |
| PB | 22.53 | 422 | 70.47 | 58.70 | 26.06 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-19T04:00:00.000Z

Total Analysts: **16**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 10 | 63% |
| Overweight | 1 | 6% |
| Hold | 4 | 25% |
| Underweight | 1 | 6% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 16.95 |
| Highest Target | 44.93 |
| Lowest Target | 12.09 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SMMT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SMMT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SMMT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SMMT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**